Soleno Therapeutics to Present at Major Conference
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a pioneer in developing novel treatments for rare diseases, has announced its participation at an upcoming conference dedicated to Prader-Willi syndrome (PWS). This exciting event will take place from June 24-28 and signifies an important moment for the company as it intends to share significant advancements in its research.
A Collaborative Platform for Progress
The conference is a unique collaboration among several leading organizations, including the Prader-Willi Syndrome Association and the Foundation for Prader-Willi Research. Marking its largest assembly yet, this gathering highlights the collective focus on enhancing life and understanding for those affected by PWS. “Our commitment to advancing the treatment of rare disorders underscores the importance of community and advocacy,” stated Dr. Anish Bhatnagar, CEO of Soleno Therapeutics. This event coincides with a milestone anniversary for PWSA | USA, emphasizing the strides made in advocacy and treatment strategies.
Key Presentations at the Conference
Soleno will lead a range of presentations, including one oral and six poster sessions detailing research findings and data from pivotal studies. Among the most anticipated presentations is an oral report on the long-term efficacy of Diazoxide Choline Extended-Release (DCCR) tablets, developed specifically for individuals with PWS. Dr. Evelien Gevers will present important findings at this session, illustrating the impact of DCCR on managing hyperphagia.
Poster Highlights
In addition to the oral presentation, several poster presentations will delve into various aspects of PWS treatment and patient experiences. Notable topics include swallowing compliance, emotional factors involved with hyperphagia, and changes in body composition related to DCCR treatment. Each poster aims to shed light on the multifaceted challenges faced by individuals with PWS.
Understanding Prader-Willi Syndrome
PWS is a complex genetic disorder triggered by anomalies in gene expression on chromosome 15 and is characterized by several life-altering symptoms, particularly an uncontrollable urge to eat known as hyperphagia. This can lead to severe health complications including obesity and diabetes. The Prader-Willi Syndrome Association estimates a prevalence of 1 in 15,000 live births. Thus, continuous research and advancements in therapeutic responses are vital for improving the lives of those affected.
About Soleno Therapeutics
Soleno is not just focused on research; it has developed VYKAT™ XR, an FDA-approved daily oral treatment aimed at mitigating the effects of hyperphagia in PWS patients aged four and older. With ongoing studies and commitment to community engagement, Soleno Therapeutics is positioned to make significant contributions to the landscape of rare disease therapeutics.
Frequently Asked Questions
1. What is the significance of the conference for Soleno Therapeutics?
This conference serves as a crucial platform for Soleno to present its research findings, foster collaboration with advocacy groups, and enhance understanding of PWS.
2. Who will present the oral session at the conference?
Dr. Evelien Gevers will present key findings on Diazoxide Choline Extended-Release tablets.
3. What topics will be covered in the poster presentations?
Subjects include the efficacy and safety of DCCR tablets, emotional impacts of hyperphagia, and swallowing compliance among patients.
4. How prevalent is Prader-Willi syndrome?
The condition occurs in approximately 1 in 15,000 live births, making awareness and research crucial.
5. What is VYKAT™ XR?
VYKAT™ XR is an FDA-approved medication developed by Soleno for managing hyperphagia in individuals with PWS.
